Edwards Lifesciences revenue and financials
$86.48Change from previous close: −0.86%Absolute change: −$0.75
In the fiscal year ended December 2025, Edwards Lifesciences reported revenue of $6.07B (+11.55% year over year). Net income was $1.07B, a net margin of 17.7%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +11.55%
- 2025 vs 2024
- Net income growth
- −74.28%
- 2025 vs 2024
- Net margin
- 17.7%
- 2024: 76.7%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1,595 | 542 | 896 | 1,218 | 1,732 | 1,054 | 1,183 | 927 | 1,001 | 704 |
| Depreciation and amortization | 157 | 155 | 145 | 140 | 135 | 107 | 89.3 | 77.4 | 81.9 | 71.2 |
| Capital expenditure | -260 | -252 | -253 | -245 | -326 | -407 | -254 | -239 | -168 | -176 |
| Investing cash flow | -713 | 2,313 | 174 | 252 | -1,723 | — | — | — | — | — |
| Financing cash flow | -957 | -983 | -711 | -1,585 | -356 | — | — | — | — | — |
| Share repurchases | -893 | -1,159 | -880 | -1,727 | -513 | -625 | -263 | -796 | -763 | -662 |
| Debt issued | — | — | 0.0 | 0.0 | 5.2 | — | — | — | — | — |
| Debt repaid | — | — | -0.3 | -0.2 | -7.0 | — | — | — | — | — |
| Effect of exchange rates | -44.8 | 38.6 | 16.8 | 19.2 | 13.9 | — | — | — | — | — |
| Net change in cash | -119 | 1,911 | 375 | -94.8 | -333 | — | — | — | — | — |
| Free cash flow | 1,335 | 290 | 643 | 974 | 1,406 | — | — | — | — | — |
| Levered free cash flow | 1,170 | 1,339 | 567 | 777 | 1,009 | — | — | — | — | — |